BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 12161471)

  • 21. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.
    Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Bruce JN
    Pituitary; 2003; 6(4):175-80. PubMed ID: 15237928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
    Jane JA; Starke RM; Elzoghby MA; Reames DL; Payne SC; Thorner MO; Marshall JC; Laws ER; Vance ML
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2732-40. PubMed ID: 21715544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
    Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
    J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
    Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria.
    Ronchi CL; Varca V; Giavoli C; Epaminonda P; Beck-Peccoz P; Spada A; Arosio M
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1377-82. PubMed ID: 15585548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.
    Arafat AM; Möhlig M; Weickert MO; Perschel FH; Purschwitz J; Spranger J; Strasburger CJ; Schöfl C; Pfeiffer AF
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1254-62. PubMed ID: 18171702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinically silent somatotropinomas may be biochemically active.
    Sakharova AA; Dimaraki EV; Chandler WF; Barkan AL
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2117-21. PubMed ID: 15671111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are there alternative tests for diagnosis of acromegaly?
    Popovic V
    J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
    Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
    J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
    De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
    Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender and age in the biochemical assessment of cure of acromegaly.
    Freda PU; Landman RE; Sundeen RE; Post KD
    Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
    Grinspoon S; Clemmons D; Swearingen B; Klibanski A
    J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
    Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.
    Puder JJ; Nilavar S; Post KD; Freda PU
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1972-8. PubMed ID: 15634715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.